Publicacións nas que colabora con Mariano Barbacid Montalbán (23)

2024

  1. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 121, Núm. 36

2021

  1. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

    Cancer Cell

2020

  1. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma

    JCI Insight, Vol. 5, Núm. 15

  2. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27

    Scientific Reports, Vol. 9, Núm. 1

2017

  1. A Braf kinase-inactive mutant induces lung adenocarcinoma

    Nature, Vol. 548, Núm. 7666, pp. 239-243

  2. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma

    Oncogene, Vol. 36, Núm. 16, pp. 2309-2318

2016

  1. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

    Nature Medicine, Vol. 22, Núm. 3, pp. 270-277

  2. KRAS-driven lung adenocarcinoma: Combined DDR1/Notch inhibition as an effective therapy

    ESMO Open, Vol. 1, Núm. 5

2015

  1. Functional Reprogramming of Polyploidization in Megakaryocytes

    Developmental Cell, Vol. 32, Núm. 2, pp. 155-167

2014

  1. Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors

    Molecular and Cellular Biology, Vol. 34, Núm. 8, pp. 1452-1459

  2. Lentiviral-based approach for the validation of cancer therapeutic targets in vivo

    BioTechniques, Vol. 57, Núm. 4, pp. 179-187

  3. Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts

    Cancer Research, Vol. 74, Núm. 21, pp. 5978-5988

2012

  1. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion

    EMBO Journal, Vol. 31, Núm. 11, pp. 2498-2510

2011

  1. C-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma

    Cancer Cell, Vol. 19, Núm. 5, pp. 652-663

  2. Cdk6-dependent regulation of G1 length controls adult neurogenesis

    Stem Cells, Vol. 29, Núm. 4, pp. 713-724

  3. Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6

    Journal of Biological Chemistry, Vol. 286, Núm. 29, pp. 25531-25539

2010

  1. A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

    Cancer Cell, Vol. 18, Núm. 1, pp. 63-73

2009

  1. Overall Cdk activity modulates the DNA damage response in mammalian cells

    Journal of Cell Biology, Vol. 187, Núm. 6, pp. 773-780

2007

  1. Cdk1 is sufficient to drive the mammalian cell cycle

    Nature, Vol. 448, Núm. 7155, pp. 811-815